A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
Paula M. Fracasso(Jewish Hospital), Helen Piwnica‐Worms(Washington University in St. Louis)
Cited by 69
Related Papers
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
|Journal of Clinical Investigation|2012|222
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
|Breast Cancer Research and Treatment|2012|107
CRL4<sup>CDT2</sup> Targets CHK1 for PCNA-Independent Destruction
|Molecular and Cellular Biology|2012|79